🏢 公司NewsroomSIQwen · 实盘不做把握 7/10不做原因:证据不足
北京时间·🕒 发布 05:45:32(美东 09-08 17:45)·⟳ 抓取 05:46:04回填·⚡ 决策 09-09 07:35:13 +1h49m·48.8 天前
Shoulder Innovations（SI.US）宣布与 Catalyst OrthoScience 就全部专利诉讼达成保密和解，未披露任何金额、许可或禁令条款
事件本身是真实的一手公司公告，但唯一可交易主体 SI.US 的新增信息只有“诉讼已解决、条款保密”：既无法判断净现金/许可方向，也无法量化相对 $4.16 亿市值、$65–68M 年收入指引的重大性；诉讼自 2024 年起已长期作为风险因素披露，属存量不确定性消除而非新增预期差，盘后 1,279 股、零涨跌的市场反应印证无重定价动力。叠加日均成交额仅约 $2.26M 的薄流动性，做多/做空均无正期望，故 AVOID；对手方 Catalyst 未上市，竞争者与跨市场（A/港/日/韩）无可坐实的二阶映射。
📄 原文SI↗ 原文
Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience
GRAND RAPIDS, Mich., Sept. 8, 2026 — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage…
不做 Shoulder Innovations（SI.US）
不做：唯一可交易主体只有“保密和解”这一条新增信息——无金额、无许可/royalty、无禁令安排，既不能判定净方向（SI 是原告、Catalyst 有反诉，风险出清与放弃主张同时发生），也无法量化相对 $4.16 亿市值和 $65–68M 年收入指引的重大性；该诉讼自 2024 年起已作为存量风险因素披露，预期差接近零，盘后 1,279 股、0.00% 涨跌已印证市场不定价。叠加 20 日均成交额约 $2.26M、盘后价差 $17.98/$20.38 的薄流动性，LONG…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实层：SI 于 2026-09-08 盘后 17:45 ET 通过自有 newsroom 宣布与 Catalyst OrthoScience 就全部专利诉讼达成和解，条款保密，CEO 表述为“可接受的解决方案”。影响链：SEC 文件显示该案是 2024-02-28 SI 在特拉华州起诉 Catalyst 侵犯反向肩关节系统专利、Catalyst 反诉 SI 侵权的双向诉讼；和解同时消除 SI 面临的反诉尾部风险（禁令/赔偿）与 SI 自身主张可获得的赔偿或竞争对手退出收益，两个方向的金额都未披露，因此净效应不可判定，也无法换算成对 FY26 指引（$65–68M）或 $4.16 亿市值的比例。价格与证据层：行情显示收盘 $19.99（-1.62%），盘后 session_price 仍为 $19.99、涨跌 0.00%、成交仅 1,279 股，20 日日均成交额约 $2.26M、盘后报价 $17.98/$20.38，近 10 个交易日为温和阴跌（-3.66%/20 日），无抢跑也无反应；自家案例库对 SI.US 6 条历史决策全部为“不做”（均为会议/财报日期类噪音），无 ENTER 记录；内部 KB 的卖方覆盖（BTIG Buy/$24 PT）关注收入与单位增长，未把该诉讼作为估值变量。结论：方向不明、量级不可估、流动性差、无对手方可交易标的、无跨市场映射，给 AVOID，不输
关键理由
- 唯一可解读的正面成分是双向专利诉讼（含 Catalyst 对 SI 的侵权反诉）终结，消除核心反向肩关节产品线的禁令/赔偿尾部风险与后续诉讼费用
- 该风险自 2024 年 2 月起已在 S-1/10-K/10-Q 中作为既有风险因素披露，属存量不确定性出清而非新增业绩增量，公司 FY26 收入指引 $65–68M 未因此改变
主要风险
- 和解条款保密：可能包含 SI 付款、交叉许可或 royalty，从而带来未披露的现金流出或毛利稀释，也可能是 SI 放弃对本可获赔的侵权主张——方向与金额均未能量化业绩增量
- SI 流动性极薄（20 日均成交额约 $2.26M，盘后买卖价差 $17.98/$20.38），任何事件仓位都难以进出，滑点风险高于潜在收益
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-08-06 · 影响 weakens
SEC 文件仅确认双向诉讼存在与案号，未披露任何索赔金额、应计负债或禁令进展；和解条款保密，无法证实“风险出清”具有可量化正价值
检索:Shoulder Innovations Catalyst OrthoScience 和解 是否含付款/许可/禁令 诉讼重大性 反诉范围 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-05-27 · 影响 none
未见业绩下修或砍单：1Q26 收入 $16.7M（同比 +64.9%）超预期，FY26 指引上调至 $65–68M，现金+证券约 $99M；但股价近 20 日 -3.66%、日均成交额仅约 $2.26M，属流动性/关注度约束而非基本面利空
检索:SI.US 近期利空 业绩下修 指引下调 流动性 成交额 减持 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-09-08 · 影响 invalidates
公告与既有披露均未提供任何指向 SI 净损害的可核验事实（无金额、无禁令、无产品限制），且事件方向不构成做空红线所要求的强空催化
检索:SI 和解是否可能包含对 SI 不利的付款或许可、是否存在新增净损害事实 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变结论：即便存在类似和解先例，条款保密使 tp/sl 无从锚定，且流动性不足以执行，仍为 AVOID
方向:无可定价先例：本次为条款保密的双边专利和解，既无金额也无禁令/许可结构，无法与任何“同类且首发可溯源”的历史事件对齐
涨幅量级:未用先例校准幅度；改以公司自身披露的诉讼背景（SI 为原告、Catalyst 反诉）与盘后零反应判断量级接近于零
形态:无先例可判断见光死/高开低走；本事件的实测盘后反应为 0.00%、1,279 股，属无反应而非派发
工具执行结果 · 成功 9 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 284 ms
{"result": "search_processed_events:agent query=`catalyst orthoscience 和解 肩关节植入物专利 | shoulder innovations catalyst orthoscience 专利诉讼和解 | shoulder innovations 和解协议 保密条款 | si nyse shoulder arthroplasty patent litigation settlement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 66.9/72 小时、992 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 ag - stock_quote 成功 stock_tools HTTP · 1,421 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - kb_search 成功 stock_tools HTTP · 3,143 ms
{ - kb_search 成功 stock_tools HTTP · 2,354 ms
{ - search_case_library 成功 stock_tools HTTP · 84 ms
{"result": "search_case_library「SI.US」—— 与这些标的相关的自家决策案例(本页 6 条,该标的全历史相关记录共 6 条；ENTER 只按该标的自己的腿统计):\n◆ SI.US：相关历史决策 6 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 6 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-09-01 UTC(CST 2026-09-02) 不做 · 事件:Shoulder - kb_fetch_document 成功 stock_tools HTTP · 35 ms
{ - kb_fetch_document 成功 stock_tools HTTP · 28 ms
{ - kb_search 成功 stock_tools HTTP · 906 ms
{
原文全文
展开原文 · 2,129 字
GRAND RAPIDS, Mich., Sept. 8, 2026 — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. (“Catalyst”) to resolve all outstanding patent litigation between the two companies. The terms of the settlement agreement are confidential.
“We are pleased to have reached a resolution with Catalyst that provides an agreeable solution to this patent dispute,” said Rob Ball, CEO of Shoulder Innovations. “Protecting our intellectual property is fundamental to ensuring that the investments we make in innovation continue to benefit Shoulder Innovations stakeholders, particularly including surgeons and patients. We believe this outcome enables us to continue to deliver on what matters most – advancing shoulder arthroplasty and delivering the best possible outcomes for patients.”
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com
The post Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience appeared first on Shoulder Innovations .
“We are pleased to have reached a resolution with Catalyst that provides an agreeable solution to this patent dispute,” said Rob Ball, CEO of Shoulder Innovations. “Protecting our intellectual property is fundamental to ensuring that the investments we make in innovation continue to benefit Shoulder Innovations stakeholders, particularly including surgeons and patients. We believe this outcome enables us to continue to deliver on what matters most – advancing shoulder arthroplasty and delivering the best possible outcomes for patients.”
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com
The post Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience appeared first on Shoulder Innovations .
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。